This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

1 Feb 2016

Sun Pharma launches imatinib mesylate in the US

Imatinib mesylate is the therapeutic equivalent to Novartis's Gleevec for indications approved by FDA.

Sun Pharma has announced the launch of imatinib mesylate tablets (therapeutic equivalent to Gleevec for indications approved by the FDA) in US market. Sun Pharma’s subsidiary received final approval for imatinib mesylate from FDA in December 2015. Being a First-to-File product, it was granted 180 days of marketing exclusivity by FDA from the time of its launch.

As part of this launch, in addition to strengthening distribution in US, the company has rolled-out a unique Sun Pharma Imatinib Mesylate Savings Card program. This program aims to deliver greater access to the drug for patients who have a commercial insurance but their out-of-pocket may exceed an affordable amount. The savings card will reduce patient’s co-payment (out-of-pocket) to $10. Sun Pharma’s Imatinib Mesylate Savings Card will also offer patients additional savings benefit of up to US$700 for a 30-day fill to offset any additional out-of-pocket cost should they be required to meet their deductible or co-insurance. Participating pharmacies across US can use the patient’s Sun Pharma’s Imatinib Mesylate Savings Card as part of this program.

Sun Pharma has also launched an exclusive patient website providing detailed information about its Imatinib Mesylate, approved indications, side effects etc. In addition, the website features detailed FAQs on the product. Sun Pharma will be supplying its Imatinib Mesylate Savings Cards to over 4,500 oncologists.

Related News